Multigene prognostic tests in breast cancer: past, present, future
There is growing consensus that multigene prognostic tests provide useful complementary information to tumor size and grade in estrogen receptor (ER)-positive breast cancers. The tests primarily rely on quantification of ER and proliferation-related genes and combine these into multivariate prediction models. Since ER-negative cancers tend to have higher proliferation rates, the prognostic value of current multigene tests in these cancers is limited. First-generation prognostic signatures (Oncotype DX, MammaPrint, Genomic Grade Index) are substantially more accurate to predict recurrence within the first 5 years than in l...
Source: Breast Cancer Research - January 27, 2015 Category: Cancer & Oncology Authors: Balázs Gy¿rffyChristos HatzisTara SanftErin HofstatterBilge AktasLajos Pusztai Source Type: research
Erratum to: ¿A novel role for ezrin in breast cancer angio/lymphangiogenesis¿
No description available (Source: Breast Cancer Research)
Source: Breast Cancer Research - January 23, 2015 Category: Cancer & Oncology Authors: Abdi GhaffariVictoria HoskinAlvin SzetoMaaike HumNavid LiaghatiKanji NakatsuDavid LeBrunYolanda MadarnasSandip SenGuptaBruce Elliott Source Type: research
Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer
Cancer genomic DNA sequences enable identification of all mutations and suggest targets for precision medicine. The identities and patterns of the mutations themselves also provide critical information for deducing the originating DNA damaging agents, causal molecular mechanisms, and thus additional therapeutic targets. A classic example is ultraviolet light, which crosslinks adjacent pyrimidines and leads to C-to-T transitions. A new example is the DNA cytosine deaminase APOBEC3B, which was identified recently as a source of DNA damage and mutagenesis in breast, head/neck, cervix, bladder, lung, ovary, and to lesser exten...
Source: Breast Cancer Research - January 21, 2015 Category: Cancer & Oncology Authors: Reuben Harris Source Type: research
Loss of Periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity
Conclusion:
Together our data suggest that loss of Postn in an ErbB2/Neu/HER2 overexpression model results in apocrine-like tumors that activate an AR-dependent pathway. This may have important implications for the treatment of breast cancers involving the therapeutic targeting of periostin or Notch signaling. (Source: Breast Cancer Research)
Source: Breast Cancer Research - January 16, 2015 Category: Cancer & Oncology Authors: Roshan SriramVivian LoBenjamin PryceLilia AntonovaAlan MearsManijeh DaneshmandBruce McKaySimon ConwayWilliam MullerLuc Sabourin Source Type: research
Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death
Conclusion:
Overall, these results demonstrate that constitutive overexpression of ISGs enhances the progression of AI-resistant breast cancer and that suppression of IFITM1 and other ISGs sensitizes AI-resistant cells to estrogen-induced cell death. (Source: Breast Cancer Research)
Source: Breast Cancer Research - January 15, 2015 Category: Cancer & Oncology Authors: Hye ChoiAsona LuiJoshua OgonyRifat JanPeter SimsJoan Lewis-Wambi Source Type: research
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
Conclusions:
In addition to driving TNBC tumor formation, BRCA1-IRIS overexpression drives their intrinsic and acquired paclitaxel resistance, partly by activating autocrine signaling loops EGF/EGFR-ErbB2 and NRG1/ErbB2-ErbB3. These loops activate AKT, causing FOXO3a degradation and survivin overexpression. Taken together, this underscores the need for BRCA1-IRIS specific therapy and strongly suggests that BRCA1-IRIS and/or signaling loops activated by it could be rational therapeutic targets for advanced TNBCs. (Source: Breast Cancer Research)
Source: Breast Cancer Research - January 13, 2015 Category: Cancer & Oncology Authors: Zannel BlanchardBibbin PaulBarbara CraftWael ElShamy Source Type: research
Circulating tumor cells in newly diagnosed inflammatory breast cancer
IntroductionCirculating tumor cells (CTCs) are an independent prognostic factor for progression-free survival (PFS) and overall survival (OS) in patients with metastatic breast cancer. Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. The prognostic value of a CTC count in newly diagnosed IBC has not been established. The aim of this study was to assess the prognostic value of a baseline CTC count in patients with newly diagnosed IBC.
Methods:
This retrospective study included 147 patients with newly diagnosed IBC (77 with locally advanced and 70 with metastatic IBC) treated with neoadj...
Source: Breast Cancer Research - January 9, 2015 Category: Cancer & Oncology Authors: Michal MegoAntonio GiordanoUgo De GiorgiHiroko MasudaLimin HsuMario GiulianoTamer FouadShaheenah DawoodNaoto UenoVicente ValeroEleni AndreopoulouRicardo AlvarezWendy WoodwardGabriel HortobagyiMassimo CristofanilliJames Reuben Source Type: research
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis
Conclusion:
This study suggests that CTCs and BM-DTCs detected in BC PDX-bearing mice may represent a valuable and unique preclinical model for investigating the role of these rare cells in tumor metastases. (Source: Breast Cancer Research)
Source: Breast Cancer Research - January 9, 2015 Category: Cancer & Oncology Authors: Mario GiulianoSabrina HerreraPavel ChristinyChad ShawChad CreightonTamika MitchellRaksha BhatXiaomei ZhangSufeng MaoLacey DobroleckiAhmed Al-rawiFengju ChenBianca VenezianiXiang ZhangSusan HilsenbeckAlejandro ContrerasCarolina GutierrezRinath JeselsohnMot Source Type: research
A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation
Conclusion:
Diverse transmembrane signals are required for mammary epithelial cell growth in 2D and 3D conditions. Strikingly, we define novel roles for axonal pathfinding receptors and ligands and the endothelin receptor in both growth and differentiation. (Source: Breast Cancer Research)
Source: Breast Cancer Research - January 9, 2015 Category: Cancer & Oncology Authors: Angela BurleighSteven McKinneyJazmine BrimhallDamian YapPeter EirewSteven PoonViola NgAdrian WanLeah PrenticeLois AnnabJ BarrettCarlos CaldasConnie EavesSamuel Aparicio Source Type: research
The use of the Gail model, body mass index and SNPs to predict breast cancer among women with abnormal (BI-RADS 4) mammograms
IntroductionMammography screening results in a significant number of false-positives. The use of pre-test breast cancer risk factors to guide follow-up of abnormal mammograms could improve the positive predictive value of screening. We evaluated the use of the Gail model, body mass index (BMI), and genetic markers to predict cancer diagnosis among women with abnormal mammograms. We also examined the extent to which pre-test risk factors could reclassify women without cancer below the biopsy threshold.
Methods:
We recruited a prospective cohort of women referred to biopsy with abnormal (BI-RADS 4) mammograms. Breast cancer ...
Source: Breast Cancer Research - January 8, 2015 Category: Cancer & Oncology Authors: Anne McCarthyBrad KellerDespina KontosLeigh BoghossianErin McGuireMirar BristolJinbo ChenSusan DomchekKatrina Armstrong Source Type: research
Role of bone-anabolic agents in the treatment of breast cancer bone metastases
Skeletal metastases are an incurable complication afflicting the majority of patients who die from advanced breast cancer. They are most often osteolytic, characterized by net bone destruction and suppressed new bone formation. Life expectancy from first diagnosis of breast cancer bone metastases is several years, during which time skeletal-related events - including pain, fracture, hypercalcemia, and spinal cord compression - significantly degrade quality of life. The bone marrow niche can also confer hormonal and chemo-resistance. Most treatments for skeletal metastases target bone-destroying osteoclasts and are palliati...
Source: Breast Cancer Research - December 31, 2014 Category: Cancer & Oncology Authors: Attaya SuvannasankhaJohn Chirgwin Source Type: research
Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence
Conclusions:
Elafin predicts poor outcome in breast and ovarian cancer patients delineates a subset of endocrine receptor positive breast cancer patients susceptible to recurrence whom could benefit from more aggressive intervention. Our in vitro results suggest that elafin arrests cell luminal breast cancer cells, perhaps suggesting a role in tumor dormancy. (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 31, 2014 Category: Cancer & Oncology Authors: Joseph CarusoCansu KarakasJing ZhangMin YiConstance AlbarracinAysegul SahinMelissa BondyJinsong LiuKelly HuntKhandan Keyomarsi Source Type: research
Standardized uptake value of 18F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden
Introduction18F-fluorodeoxyglucose positron emission tomography (FDG-PET) can reveal the metabolic activity of malignant tumors. Recent advances in molecular works suggest that tumor biology can well predict prognosis in breast cancer. We compared the ability of maximum standardized uptake values (SUVmax) from FDG-PET with tumor burden in predicting tumor recurrence for patients with breast cancer.
Methods:
Between April 2004 and May 2009, 496 breast cancer patients who underwent pre-operative FDG-PET were retrospectively identified. SUVmax was obtained from FDG-PET, and the cut-off point was defined using a time-dependent...
Source: Breast Cancer Research - December 31, 2014 Category: Cancer & Oncology Authors: Sung AhnJong ParkHak LeeHak LeeTae JeonKyunghwa HanSeung LeeSeung DongYoung RyuEun SonJoon Jeong Source Type: research
Toca-1 is suppressed by p53 to limit breast cancer cell invasion and tumor metastasis
Conclusions:
Based on these findings, we conclude that loss of p53 tumor suppressor function in breast cancers leads to upregulation of Toca-1, and results in enhanced risk of developing metastatic disease. (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 30, 2014 Category: Cancer & Oncology Authors: Harish ChanderColin BrienPeter TruesdellKathleen WattJalna MeensColleen SchickDoris GermainAndrew Craig Source Type: research
